The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Multiple Sclerosis: A Review
Open accessAbstract
5and 50% of patients will need help walking within 15 years after the onset of the disease. 6 Twice as many women are affected as men, and persons of Northern European descent appear to be at highest risk for MS. 2,7 The disease is diagnosed on the basis of clinical findings and supporting evidence from ancillary tests, such as magnetic resonance imaging (MRI) of the brain and examination of the cerebrospinal fluid (CSF). MS typically presents in adults 20 to 45 years of age; occasionally, it presents in childhood or late middle age. 7
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Beck, R. W., Cleary, P. A., Trobe, J. D., Kaufman, D. I., Kupersmith, M. J., Paty, D. W., & Brown, C. H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292403 · Cited by 579
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
Li, D. K. B., Paty, D. W., & UBC MS/MRI Analysis Research Group and the PRISMS Study Group (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-p · Cited by 380
Milligan, N. M., Newcombe, R., & Compston, D. A. (1987) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.50.5.511 · Cited by 364
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Review: cytokines and the pathogenesis of multiple sclerosis
Navikas, V., & Link, H. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960815)45:4<322::aid-jnr1>3.0.co;2-b · Cited by 328
The paradigm of Th1 and Th2 cytokines: Its Relevance to Autoimmunity and Allergy
Singh, V. K., Mehrotra, S., & Agarwal, S. S. (1999) · Immunologic Research · doi:10.1007/bf02786470 · Cited by 318
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Interferon-β mechanisms of action in multiple sclerosis
Dhib-Jalbut, S., & Marks, S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97d99 · Cited by 298
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS
Weinshenker, B. G. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70257-7 · Cited by 232
Diagnosis and management of multiple sclerosis.
Calabresi, P. A. (2004) · PubMed · Cited by 230
Khatri, B., Barkhof, F., Comi, G., Hartung, H.-P., Kappos, L., Montalban, X., Pelletier, J., Stites, T., Wu, S., Holdbrook, F., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70099-0 · Cited by 218
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
Naismith, R. T., Piccio, L., Lyons, J. A., Lauber, J., Tutlam, N. T., Parks, B. J., Trinkaus, K., Song, S. K., & Cross, A. H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24373 · Cited by 217
Ford, C., Goodman, A., Johnson, K., Kachuck, N., Lindsey, J., Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., et al. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509358088 · Cited by 207
Yang, J.-S., Xu, L.-Y., Xiao, B.-G., Hedlund, G., & Link, H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.02.016 · Cited by 175
Bertolotto, A., Malucchi, S., Sala, A., Orefice, G., Carrieri, P. B., Capobianco, M., Milano, E., Melis, F., & Giordana, M. T. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.2.148 · Cited by 163
Ibudilast in relapsing-remitting multiple sclerosis
Barkhof, F., Hulst, H. E., Drulovic, J. S., Uitdehaag, B. M. J., Matsuda, K., & Landin, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d7d651 · Cited by 154
Multiple Sclerosis and Other Demyelinating Diseases
Bendszus, M., & Storch-Hagenlocher, B. (2013) · Medical radiology · doi:10.1007/174_2012_787 · Cited by 149
Pathophysiology of multiple sclerosis and the place of teriflunomide
Gold, R., & Wolinsky, J. S. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01444.x · Cited by 145
Insight into the mechanism of laquinimod action
Brück, W., & Wegner, C. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.02.019 · Cited by 126
Fleischmann, R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24906 · Cited by 112
Management of worsening multiple sclerosis with mitoxantrone: A review
Fox, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.013 · Cited by 102
Treatment with Interferon Beta-1b Improves Quality of Life in Multiple Sclerosis
Rice, G. P. A., Oger, J., Duquette, P., Francis, G., Bélanger, M., Laplante, S., & Grenier, J.-F. (1999) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000038x · Cited by 82
Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases
Kovarsky, J. (1983) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(83)90016-1 · Cited by 81
Review of teriflunomide and its potential in the treatment of multiple sclerosis
Kieseier, B. C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4474 · Cited by 79
Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab
Klotz, L., Meuth, S. G., & Wiendl, H. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.04.006 · Cited by 75
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
Rojas, M. A., Carlson, N. G., Miller, T. L., & ROSE, J. W. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609337992 · Cited by 26
Tselis, A. C. (2010) · PubMed · Cited by 10
BG00012 - A Novel Oral Therapy in Development for the Treatment of Multiple Sclerosis
Fox, R. J. (2008) · European Neurological Review · doi:10.17925/enr.2008.03.01.99 · Cited by 4
(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
N-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 382
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Physical activity and autoimmune diseases: Get moving and manage the disease
Sharif, K., Watad, A., Bragazzi, N. L., Lichtbroun, M., Amital, H., & Shoenfeld, Y. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.010 · Cited by 324
Metadata
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1973-05-19
- Volume
- 2
- Issue
- 5863
- Pages
- 432-432
- ISSN
- 0007-1447 (ISSN-L)
- 1468-5833
- OpenAlex
- W2108718949
- Cited by
- 488
- References
- 47
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.